
News|Articles|February 13, 2019
Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Author(s)Drew Boxler
Advertisement
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
2
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
3
Study Links Live Flu Vaccine With Rise in Pneumococcal Disease
4
2026-2027 Respiratory Vaccine Guidance for Pharmacists
5































